NASDAQ:ACHV - Achieve Life Sciences Stock Price, News & Analysis

-0.04 (-2.02 %)
(As of 08/23/2019 04:00 PM ET)
Today's Range
Now: $1.94
50-Day Range
MA: $1.84
52-Week Range
Now: $1.94
Volume160,393 shs
Average Volume81,739 shs
Market Capitalization$15.71 million
P/E RatioN/A
Dividend YieldN/A
Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes smoking cessation aids in the United States and internationally. The company offers Cytisine, a plant-based alkaloid that interacts with nicotine receptors in the brain to help reduce the severity of nicotine withdrawal symptoms. It has a license agreement with Sopharma AD and University of Bristol. Read More…

Industry, Sector and Symbol

Industry Diagnostic substances
Current SymbolNASDAQ:ACHV



Sales & Book Value

Annual Sales$5.06 million
Book Value$1.42 per share


Net Income$-12,690,000.00


Market Cap$15.71 million
Next Earnings Date11/6/2019 (Estimated)
OptionableNot Optionable

Receive ACHV News and Ratings via Email

Sign-up to receive the latest news and ratings for ACHV and its competitors with MarketBeat's FREE daily newsletter.

Achieve Life Sciences (NASDAQ:ACHV) Frequently Asked Questions

What is Achieve Life Sciences' stock symbol?

Achieve Life Sciences trades on the NASDAQ under the ticker symbol "ACHV."

When did Achieve Life Sciences' stock split? How did Achieve Life Sciences' stock split work?

Shares of Achieve Life Sciences reverse split on the morning of Thursday, May 24th 2018. The 1-10 reverse split was announced on Wednesday, May 23rd 2018. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, May 23rd 2018. An investor that had 100 shares of Achieve Life Sciences stock prior to the reverse split would have 10 shares after the split.

How were Achieve Life Sciences' earnings last quarter?

Achieve Life Sciences Inc (NASDAQ:ACHV) announced its earnings results on Thursday, August, 8th. The biopharmaceutical company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.33) by $0.17. View Achieve Life Sciences' Earnings History.

When is Achieve Life Sciences' next earnings date?

Achieve Life Sciences is scheduled to release their next quarterly earnings announcement on Wednesday, November 6th 2019. View Earnings Estimates for Achieve Life Sciences.

What price target have analysts set for ACHV?

2 equities research analysts have issued 12-month price objectives for Achieve Life Sciences' shares. Their forecasts range from $6.00 to $20.00. On average, they expect Achieve Life Sciences' share price to reach $13.00 in the next year. This suggests a possible upside of 570.1% from the stock's current price. View Analyst Price Targets for Achieve Life Sciences.

What is the consensus analysts' recommendation for Achieve Life Sciences?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Achieve Life Sciences in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Achieve Life Sciences.

What are Wall Street analysts saying about Achieve Life Sciences stock?

Here are some recent quotes from research analysts about Achieve Life Sciences stock:
  • 1. Maxim Group analysts commented, "Achieve announced this morning that the company’s collaboration with the National Center for Complementary and Integrative Health (NCCIH) of the NIH has been extended." (7/24/2019)
  • 2. According to Zacks Investment Research, "Achieve Life Sciences Inc. is a pharmaceutical company. It develops and commercializes cytisine treatment to help people battling nicotine addiction. The Company's product candidates include Custirsen, Apatorsen and OGX-225. Achieve Life Sciences Inc., formerly known as OncoGenex Pharmaceuticals Inc., is based in Bothell, United States. " (1/8/2019)

Has Achieve Life Sciences been receiving favorable news coverage?

News headlines about ACHV stock have been trending positive on Saturday, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Achieve Life Sciences earned a news sentiment score of 2.5 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 6.0 out of 10, meaning that recent news coverage is somewhat likely to have an impact on the stock's share price in the immediate future. View News Stories for Achieve Life Sciences.

Are investors shorting Achieve Life Sciences?

Achieve Life Sciences saw a decline in short interest in July. As of July 31st, there was short interest totalling 361,300 shares, a decline of 12.6% from the June 30th total of 413,200 shares. Based on an average trading volume of 202,900 shares, the short-interest ratio is currently 1.8 days. Currently, 5.7% of the shares of the company are sold short. View Achieve Life Sciences' Current Options Chain.

Who are some of Achieve Life Sciences' key competitors?

What other stocks do shareholders of Achieve Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Achieve Life Sciences investors own include Synergy Pharmaceuticals (SGYP), Novavax (NVAX), SLS International (SLS), Immunomedics (IMMU), Exelixis (EXEL), Inovio Pharmaceuticals (INO), Verastem (VSTM), Arena Pharmaceuticals (ARNA), Celldex Therapeutics (CLDX) and Amicus Therapeutics (FOLD).

Who are Achieve Life Sciences' key executives?

Achieve Life Sciences' management team includes the folowing people:
  • Dr. Richard A. B. Stewart, Chairman & CEO (Age 60)
  • Dr. Anthony Clarke, Pres, Chief Scientific Officer & Director (Age 63)
  • Mr. John A. Bencich, Exec. VP, CFO & COO (Age 42)
  • Dr. Cindy Jacobs, Exec. VP & Chief Medical Officer (Age 61)
  • Ms. Jaime Xinos, Exec. VP of Commercial

Who are Achieve Life Sciences' major shareholders?

Achieve Life Sciences' stock is owned by many different of institutional and retail investors. Top institutional investors include Sio Capital Management LLC (6.48%), Renaissance Technologies LLC (3.97%), Vanguard Group Inc. (3.39%), Searle & CO. (1.93%), Worth Venture Partners LLC (0.89%) and Jane Street Group LLC (0.21%). Company insiders that own Achieve Life Sciences stock include Armistice Capital Master Fund and Richard Alistair Stewart. View Institutional Ownership Trends for Achieve Life Sciences.

Which major investors are selling Achieve Life Sciences stock?

ACHV stock was sold by a variety of institutional investors in the last quarter, including Worth Venture Partners LLC. View Insider Buying and Selling for Achieve Life Sciences.

Which major investors are buying Achieve Life Sciences stock?

ACHV stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Sio Capital Management LLC, Searle & CO., Renaissance Technologies LLC and Jane Street Group LLC. Company insiders that have bought Achieve Life Sciences stock in the last two years include Armistice Capital Master Fund and Richard Alistair Stewart. View Insider Buying and Selling for Achieve Life Sciences.

How do I buy shares of Achieve Life Sciences?

Shares of ACHV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Achieve Life Sciences' stock price today?

One share of ACHV stock can currently be purchased for approximately $1.94.

How big of a company is Achieve Life Sciences?

Achieve Life Sciences has a market capitalization of $15.71 million and generates $5.06 million in revenue each year. The biopharmaceutical company earns $-12,690,000.00 in net income (profit) each year or ($3.61) on an earnings per share basis. Achieve Life Sciences employs 13 workers across the globe.View Additional Information About Achieve Life Sciences.

What is Achieve Life Sciences' official website?

The official website for Achieve Life Sciences is

How can I contact Achieve Life Sciences?

Achieve Life Sciences' mailing address is 1040 WEST GEORGIA STREET SUITE 1030, VANCOUVER BC, V6E 4H1. The biopharmaceutical company can be reached via phone at 604-210-2217 or via email at [email protected]

MarketBeat Community Rating for Achieve Life Sciences (NASDAQ ACHV)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  251 (Vote Outperform)
Underperform Votes:  226 (Vote Underperform)
Total Votes:  477
MarketBeat's community ratings are surveys of what our community members think about Achieve Life Sciences and other stocks. Vote "Outperform" if you believe ACHV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACHV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/24/2019 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel